NEW YORK, Dec. 15 Reportlinker.com announces that a new market research report is available in its catalogue:
Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015
Advertisement
http://www.reportlinker.com/p0167308/Systemic-Lupus-Erythematosus---Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015.html
Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015
Advertisement
Summary
GlobalData, the industry analysis specialist's new report, "Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global systemic lupus erythematosus market. The report identifies the key trends shaping and driving the global systemic lupus erythematosus market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global systemic lupus erythematosus sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
Scope
The scope of the report includes:
- Annualized global systemic lupus erythematosus market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across different phases by mechanism of action being developed and emerging trends. Key classes of mechanism of action include T and B cell modulators, Immunomodulators, Hormonal Agents, phosphodiesterase type 4 inhibitor, Anti Alpha INF, Interleukin inhibitors and anti CD antigens.
- Analysis of the current and future market competition in the global systemic lupus erythematosus market. Key market players covered are F. Hoffmann-La Roche Ltd (Genentech) , MedImmune, Bristol-Myers Squibb, GlaxoSmithKline, Human Genome Sciences, UCB S.A, Amgen and Biogen Idec.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with systemic lupus erythematosus.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global systemic lupus erythematosus market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global systemic lupus erythematosus market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global systemic lupus erythematosus market landscape? - Identify, understand and capitalize.
Table of Contents
1 Systemic Lupus Erythematosus Market: Executive Summary
1.1 The Systemic Lupus Erythematosus Market is Forecast to Show Positive Growth until 2015
1.2 Major Companies Focusing on SLE Drug Development Landscape
1.3 Strong Pipeline with First-in Class Candidates Raise Hope to SLE Treatment Paradigm
1.4 High Unmet Need Continues to Remain Unaddressed
2 Table Of Contents
2.1 List of Tables
2.2 List of Figures
3 Global Systemic Lupus Erythematosus Market: Market Characterization
3.1 Overview
3.2 Systemic Lupus Erythematosus Market Size
3.3 Systemic Lupus Erythematosus Market Forecast and CAGR
3.4 Drivers and Barriers for Systemic Lupus Erythematosus Market
3.4.1 Drivers for Systemic Lupus Erythematosus Market
3.4.2 Barriers for Systemic Lupus Erythematosus Market
3.5 Opportunity and Unmet Need
3.6 Key Takeaway
4 Global Systemic Lupus Erythematosus Market : Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Major Therapies and Off-Label Marketed Products in Systemic Lupus Erythematosus Market
4.3.1 Non-steroidal anti-inflammatory drugs (NSAIDs)
4.3.1.1 Overview
4.3.1.2 Aspirin
4.3.2 Anti-Malarials
4.3.2.1 Overview
4.3.2.2 Plaquenil (Hydroxychloroquine)
4.3.3 Corticosteroids
4.3.3.1 Overview
4.3.3.2 Prednisone
4.3.4 Immunosuppressant or Cytotoxic Drugs
4.3.4.1 Overview
4.3.4.2 CellCept (Mycophenolate Mofetil)
4.3.4.3 Rituxan (rituximab)
4.4 Key Takeaway
5 Global Systemic Lupus Erythematosus Market : Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Technology Trends Analytic Framework
5.3 Systemic Lupus Erythematosus Therapeutics -Promising Drugs under Clinical Development
5.4 Molecule Profile for Promising Drugs under Clinical Development
5.4.1 BENLYSTA (belimumab)
5.4.1.1 Overview
5.4.1.2 Efficacy
5.4.1.3 Safety
5.4.1.4 Clinical Study Details
5.4.2 Atacicept
5.4.2.1 Overview
5.4.2.2 Efficacy
5.4.2.3 Safety
5.4.2.4 Clinical Study Details
5.4.3 Ocrelizumab (Humanized Anti-CD20 mAb)
5.4.3.1 Overview
5.4.3.2 Efficacy
5.4.3.3 Safety
5.4.3.4 Clinical Study Details
5.4.4 Prestara(TM)
5.4.4.1 Overview
5.4.4.2 Efficacy
5.4.4.3 Safety
5.4.4.4 Clinical Study Details
5.4.5 Epratuzumab
5.4.5.1 Overview
5.4.5.2 Efficacy
5.4.5.3 Safety
5.4.5.4 Clinical Study Details
5.4.6 Lupuzor(TM)
5.4.6.1 Overview
5.4.6.2 Efficacy
5.4.6.3 Safety
5.4.6.4 Clinical Study Details
5.5 Systemic Lupus Erythematosus Therapeutics Market - Clinical Pipeline by Mechanism of Action
5.6 Systemic Lupus Erythematosus - Pipeline by Clinical Phases of Development
5.6.1 Systemic Lupus Erythematosus Therapeutics - Phase III Clinical Pipeline
5.6.2 Systemic Lupus Erythematosus Therapeutics - Phase II Clinical Pipeline
5.6.3 Systemic Lupus Erythematosus Therapeutics - Phase I Clinical Pipeline
5.6.4 Systemic Lupus Erythematosus Therapeutics - Preclinical Pipeline
5.6.5 Systemic Lupus Erythematosus Therapeutics - Discovery Pipeline
5.7 Discontinued / Suspended Drugs for Systemic Lupus Erythematosus
5.8 Key Takeaway
6 Global Systemic Lupus Erythematosus Market : Implications for Future Market Competition
7 Global Systemic Lupus Erythematosus Market : Future Players in SLE Market
7.1 Introduction
7.2 Biogen Idec
7.2.1 Overview
7.2.2 Autoimmune Portfolio
7.2.2.1 Marketed Products
7.2.2.2 Pipeline Products
7.2.3 Systemic Lupus Erythematosus Product Portfolio
7.2.3.1 Ocrelizumab (RG1594)
7.2.3.2 Anti-CD40CL
7.3 MedImmune
7.3.1 Overview
7.3.2 Autoimmune Portfolio
7.3.2.1 Marketed Products
7.3.2.2 Pipeline Products
7.3.3 Autoimmune Product Portfolio
7.3.3.1 MEDI-545 (MDX-1103)
7.3.3.2 Anti-ILT-7
7.4 F. Hoffmann-La Roche Ltd (Genentech, Inc)
7.4.1 Overview
7.4.2 Autoimmune Portfolio
7.4.2.1 Marketed Products
7.4.2.2 Pipeline Products
7.4.3 Systemic Lupus Erythematosus Product Portfolio
7.4.3.1 RG7415 (rontalizumab)
7.5 Amgen Inc
7.5.1 Overview
7.5.2 Autoimmune Portfolio
7.5.2.1 Marketed Products
7.5.2.2 Pipeline Products
7.5.3 Systemic Lupus Erythematosus Product Portfolio
7.5.3.1 AMG 811
7.5.3.2 AMG 557
7.6 Bristol-Myers Squibb
7.6.1 Overview
7.6.2 Autoimmune Portfolio
7.6.2.1 Marketed Products
7.6.2.2 Pipeline Products
7.6.3 Systemic Lupus Erythematosus Product Portfolio
7.6.3.1 Abatacept
7.7 UCB S.A
7.7.1 Overview
7.7.2 Autoimmune Portfolio
7.7.2.1 Marketed Products
7.7.2.2 Pipeline Products
7.7.3 Systemic Lupus Erythematosus Product Portfolio
7.7.3.1 Epratuzumab
7.8 GlaxoSmithKline plc
7.8.1 Overview
7.8.2 Autoimmune Portfolio
7.8.2.1 Marketed Products
7.8.2.2 Pipeline Products
7.8.3 Systemic Lupus Erythematosus Product Portfolio
7.8.3.1 Belimumab (BENLYSTA)
7.8.3.2 Prestara
8 Global Systemic Lupus Erythematosus Market : Appendix
8.1 Definitions
8.2 Acronyms
8.3 Research Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Forecasting
8.3.3.1 Epidemiology-based Forecasting
8.3.4 Primary Research
8.3.5 Expert Panel validation
8.4 Contact Us
8.5 Disclaimer
8.6 Sources
List of Tables
Table 1: Global SLE Therapeutics Market, Revenue ($m), 2000-2008
Table 2: Global SLE Therapeutics Market, Revenue ($m), 2008-2015
Table 3: Systemic Lupus Erythematosus Therapeutics - Most Promising Drugs Under Clinical Development, 2009
Table 4: Systemic Lupus Erythematosus Therapeutics - Phase III Clinical Pipeline, 2009
Table 5: Systemic Lupus Erythematosus Therapeutics - Phase II Clinical Pipeline, 2009
Table 6: Systemic Lupus Erythematosus Therapeutics - Phase I Clinical Pipeline, 2009
Table 7: Systemic Lupus Erythematosus Therapeutics - Preclinical Pipeline, 2009
Table 8: Systemic Lupus Erythematosus Therapeutics - Discovery Pipeline, 2009
Table 9: List of Discontinued/Suspended Drugs for Systemic Lupus Erythematosus, 2009
Table 10: Biogen Idec - Autoimmune Marketed Products, 2009
Table 11: Biogen Idec - Autoimmune Pipeline Products, 2009
Table 12: MedImmune - Autoimmune Pipeline Products, 2009
Table 13: F. Hoffmann-La Roche Ltd - Autoimmune Marketed Products, 2009
Table 14: F. Hoffmann-La Roche Ltd - Autoimmune Pipeline Products, 2009
Table 15: Amgen Inc - Autoimmune Marketed Products, 2009
Table 16: Amgen Inc - Autoimmune Pipeline Products, 2009
Table 17: Bristol-Myers Squibb - Autoimmune Marketed Products, 2009
Table 18: Bristol-Myers Squibb - Autoimmune Pipeline Products, 2009
Table 19: UCB S.A - Autoimmune Marketed Products, 2009
Table 20: UCB S.A - Autoimmune Pipeline Products, 2009
Table 21: GlaxoSmithKline plc- Autoimmune Marketed Products, 2009
Table 22: GlaxoSmithKline plc - Autoimmune Pipeline Products, 2009
List of Figures
Figure 1: Global SLE Therapeutics Market Revenue ($m) 2000-2015
Figure 2: Opportunity and Unmet Need, 2009
Figure 3: Strategic Competitor Assessment of the Major Off-Label Products in SLE, 2009
Figure 4: Technology Trends Analytic Framework of the SLE Pipeline, 2009
Figure 5: Technology Trends Analytic Framework of the SLE Pipeline- Description, 2009
Figure 6: SLE Market- Clinical Pipeline by Mechanism of Action, 2009
Figure 7: Systemic Lupus Erythematosus Pipeline by Phase of Clinical Development, 2009
Figure 8: Implications for Future Market Competition in the SLE Market, 2009
Figure 9: Systemic Lupus Erythematosus Market - Clinical Pipeline by Company, 2009
Figure 10: GlobalData Methodology
Figure 11: GlobalData Market Forecasting Model
Companies mentioned
GlaxoSmithKline Plc, Human Genome Sciences, F. Hoffmann-La Roche Ltd, Genentech, MedImmune, Bristol-Myers Squibb , UCB S.A, Amgen, Biogen Idec, ImmuPharma, Merck Serono, ZymoGenetics, Genelabs Technologies, ImmuPharma, Cephalon Inc,
To order this report:
Pharmaceutical Industry: Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015
More Market Research Report
Contact Nicolas Bombourg Reportlinker Email: nbo@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626
SOURCE Reportlinker
